nach oben

Der Nervenarzt

Erschienen in:

01.10.2003 | Übersicht

Chemokine

Neue Therapieansätze für die Multiple Sklerose?

verfasst von: Dr. C. Trebst, R. M. Ransohoff, A. Windhagen, M. Stangel

Erschienen in: Der Nervenarzt | Ausgabe 10/2003

Einloggen, um Zugang zu erhalten

Zusammenfassung

Einer der kritischen Schritte in der pathogenetischen Kaskade der Multiplen Sklerose (MS) ist die Einwanderung von mononukleären Zellen (Lymphozyten und Monozyten) in das zentrale Nervensystem (ZNS). Aufgrund ihrer Beteiligung an der Migration von Leukozyten unter physiologischen und pathologischen Bedingungen liegt eine Beteiligung von Chemokinen an diesem Prozess nahe. Dieses komplexe System von Liganden und Rezeptoren scheint für ein therapeutisches Eingreifen besonders interessant, da neben Peptidantagonisten auch kleine molekulare Antagonisten für den klinischen Gebrauch zur Verfügung stehen. Zu den möglicherweise bei der MS therapeutisch interessanten Chemokinrezeptoren gehören CCR1, CCR2, CCR5 und CXCR3 und ihre entsprechenden Liganden.

Dieser Übersichtsartikel fasst den heutigen Wissensstand zu der Rolle von Chemokinen und Chemokinrezeptoren in der Pathogenese der MS zusammen und eröffnet erste Ansätze der auf diesen Kenntnissen beruhenden pharmakologisch-therapeutischen Interventionsmöglichkeiten, die in Kürze auch in klinischen Studien an MS-Patienten geprüft werden.

Anders HJ, Vielhauer V, Frink M et al. (2002) A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J Clin Invest 109:251–259CrossRefPubMed

Auten RL, Richardson RM, White JR, Mason SN, Vozzelli MA, Whorton MH (2001) Nonpeptide CXCR2 antagonist prevents neutrophil accumulation in hyperoxia-exposed newborn rats. J Pharmacol Exp Ther 299:90–95PubMed

Balashov KE, Rottman JB, Weiner HL, Hancock WW (1999) CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci U S A 96:6873–6878CrossRefPubMed

Barcellos LF, Schito AM, Rimmler JB et al. (2000) CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group Immunogenetics 51:281–288CrossRef

Bedke J, Stojanovic T, Grone HJ et al. (2002) Met-RANTES improves acute-rejection-induced microvascular injury in rat small bowel transplantation. Transplant Proc 34:1049CrossRefPubMed

Bennetts BH, Teutsch SM, Buhler MM, Heard RN, Stewart GJ (1997) The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum Immunol 58:52–59CrossRefPubMed

Dumont RA, Car BD, Voitenok NN, Junker U, Moser B, Zak O, O'Reilly T (2000) Systemic neutralization of interleukin-8 markedly reduces neutrophilic pleocytosis during experimental lipopolysaccharide-induced meningitis in rabbits. Infect Immun 68:5756–5763CrossRefPubMed

Fife BT, Kennedy KJ, Paniagua MC, Lukacs NW, Kunkel SL, Luster AD, Karpus WJ (2001) CXCL10 (IFN-gamma-inducible protein-10) control of encephalitogenic CD4+ T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis. J Immunol 166:7617–7624PubMed

Fiten P, Vandenbroeck K, Dubois B et al. (1999) Microsatellite polymorphisms in the gene promoter of monocyte chemotactic protein-3 and analysis of the association between monocyte chemotactic protein-3 alleles and multiple sclerosis development. J Neuroimmunol 95:195–201CrossRefPubMed

10.

Franciotta D, Martino G, Zardini E, Furlan R, Bergamaschi R, Andreoni L, Cosi V (2001) Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 115:192–198CrossRefPubMed

11.

Glabinski AR, Tani M, Tuohy VK, Tuthill RJ, Ransohoff RM (1995) Central nervous system chemokine mRNA accumulation follows initial leukocyte entry at the onset of acute murine experimental autoimmune encephalomyelitis. Brain Behav Immun 9:315–330CrossRefPubMed

12.

Gong JH, Ratkay LG, Waterfield JD, Clark-Lewis I (1997) An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J Exp Med 186:131–137CrossRefPubMed

13.

Grone HJ, Weber C, Weber KS et al. (1999) Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. FASEB J 13:1371–1383PubMed

14.

Harada A, Sekido N, Akahoshi T, Wada T, Mukaida N, Matsushima K (1994) Essential involvement of interleukin-8 (IL-8) in acute inflammation. J Leukoc Biol 56:559–564PubMed

15.

Hesselgesser J, Ng HP, Liang M et al. (1998) Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor. J Biol Chem 273:15687–15692CrossRefPubMed

16.

Horuk R, Shurey S, Ng HP et al. (2001) CCR1-specific non-peptide antagonist: efficacy in a rabbit allograft rejection model. Immunol Lett 76:193–201

17.

Huang DR, Wang J, Kivisäkk P, Rollins BJ, Ransohoff RM (2001) Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J Exp Med 193:713–726CrossRefPubMed

18.

Hulkower K, Brosnan CF, Aquino DA et al. (1993) Expression of CSF-1 c-fms and MCP-1 in the central nervous system of rats with experimental allergic encephalomyelitis. J Immunol 150:2525–2533PubMed

19.

Karpus WJ, Lukacs NW, McRae BL, Strieter RM, Kunkel SL, Miller SD (1995) An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease experimental autoimmune encephalomyelitis. J Immunol 155:5003–5010PubMed

20.

Kennedy KJ, Strieter RM, Kunkel SL, Lukacs NW, Karpus WJ (1998) Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1alpha and monocyte chemotactic protein-1- J Neuroimmunol 92:98–108

21.

Kivisäkk P, Trebst C, Liu Z et al. (2002) T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking. Clin Exp Immunol 129:510–518CrossRefPubMed

22.

Lloyd CM, Minto AW, Dorf ME et al. (1997) RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med 185:1371–1380CrossRefPubMed

23.

Ma Q, Jones D, Borghesani PR et al. (1998) Impaired B-lymphopoiesis myelopoiesis and derailed cerebellar neuron migration in C. Proc Natl Acad Sci U S A 95:9448–9453CrossRefPubMed

24.

Mahad DJ, Howell SJ, Woodroofe MN (2002) Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 72:498–502PubMed

25.

Mahad D, Woodroofe M, Howell S (2000) Chemokine expression in cerebrospinal fluid of multiple sclerosis. Ann Neurol 48:452 (abstract)

26.

Matsui M, Weaver J, Proudfoot AE et al. (2002) Treatment of experimental autoimmune encephalomyelitis with the chemokine receptor antagonist Met-RANTES. J Neuroimmunol 128:16–22CrossRefPubMed

27.

Matsumoto T, Ikeda K, Mukaida N, Harada A, Matsumoto Y, Yamashita J, Matsushima K (1997) Prevention of cerebral edema and infarct in cerebral reperfusion injury by an antibody to interleukin-8. Lab Invest 77:119–125PubMed

28.

McManus C, Berman JW, Brett FM, Staunton H, Farrell M, Brosnan CF (1998) MCP-1 MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. J Neuroimmunol 86:20–29CrossRefPubMed

29.

Miller DH, Khan OA, Sheremata WA et al. (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348:15–23CrossRefPubMed

30.

Misu T, Onodera H, Fujihara K et al. (2001) Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: imbalance of Th1/Th2-associated chemokine signaling. J Neuroimmunol 114:207–212CrossRefPubMed

31.

Murphy PM, Baggiolini M, Charo IF et al. (2000) International union of pharmacology XXII Nomenclature for chemokine receptors. Pharmacol Rev 52:145–176PubMed

32.

Nguyen D, Stangel M (2001) Expression of the chemokine receptors CXCR1 and CXCR2 in rat oligodendroglial cells. Brain Res Dev Brain Res 128:77–81CrossRefPubMed

33.

Ostergaard C, Yieng-Kow RV, Larsen CG et al. (2000) Treatment with a monocolonal antibody to IL-8 attenuates the pleocytosis in experimental pneumococcal meningitis in rabbits when given intravenously but not intracisternally. Clin Exp Immunol 122:207–211CrossRefPubMed

34.

Plater-Zyberk C, Hoogewerf AJ, Proudfoot AE, Power CA, Wells TN (1997) Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol Lett 57:117–120CrossRefPubMed

35.

Proudfoot AE, Handel TM, Johnson Z et al. (2003) Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci U S A 100:1885–1890CrossRefPubMed

36.

Proudfoot AE, Power CA, Wells TN (2000) The strategy of blocking the chemokine system to combat disease. Immunol Rev 177:246–256

37.

Rossi D, Zlotnik A (2000) The biology of chemokines and their receptors. Annu Rev Immunol 18:217–242PubMed

38.

Rottman JB, Silva R, Slavin A, Weiner HL, Gerard CG, Hancock WW (1999) Central role of CCR1+ cells in the immunopathogenesis of experimental allergic encephalomyelitis (EAE). FASEB 13:666 (abstract)

39.

Rottman JB, Slavin AJ, Silva R, Weiner HL, Gerard CG, Hancock WW (2000) Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent. Eur J Immunol 30:2372–2377CrossRefPubMed

40.

Schwarz MK, Wells TN (2002) New therapeutics that modulate chemokine networks. Nat Rev Drug Discov 1:347–358CrossRefPubMed

41.

Seet BT, McFadden G (2002) Viral chemokine-binding proteins. J Leukoc Biol 72:24–34PubMed

42.

Sellebjerg F, Madsen HO, Jensen CV, Jensen J, Garred P (2000) CCR5 delta32 matrix metalloproteinase-9 and disease activity in multiple sclerosis. J Neuroimmunol 102:98–106CrossRefPubMed

43.

Simpson J, Rezaie P, Newcombe J, Cuzner ML, Male D, Woodroofe MN (2000) Expression of the β-chemokine receptors CCR2 CCR3 and CCR5 in multiple sclerosis central nervous system tissue. J Neuroimmunol 108:192–200CrossRefPubMed

44.

Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN (1998) Expression of monocyte chemoattractant protein-1 and other β- chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J Neuroimmunol 84:238–249PubMed

45.

Sindern E, Ossege L, Patzold T, Malin J (2000) Monocyte chemotactic protein-1 (MCP-1) is increased in cerebrospinal fluid of patients with viral and bacterial meningoencephalitis but not in patients with relapsing remitting multiple sclerosis (RR-MS). Mult Scler 5:83 (abstract)

46.

Sørensen TL, Tani M, Jensen J et al. (1999) Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 103:807–815PubMed

47.

Sørensen TL, Trebst C, Kivisäkk P et al. (2002) Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system. J Neuroimmunol 127:59–68CrossRefPubMed

48.

Springer TA (1994) Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76:301–314PubMed

49.

Strunk T, Bubel S, Mascher B, Schlenke P, Kirchner H, Wandinger KP (2000) Increased numbers of CCR5+ interferon- γ- and tumor necrosis factor-α-secreting T lymphocytes in multiple sclerosis. Ann Neurol 47:269–273CrossRefPubMed

50.

Trebst C, Ransohoff RM (2001) Investigating Chemokines and Chemokine Receptors in Patients With Multiple Sclerosis:Opportunities and Challenges. Arch Neurol 58:1975–1980CrossRefPubMed

51.

Trebst C, Sørensen, TL Kivisäkk P et al. (2001) CCR1+/CCR5+ Mononuclear Phagocytes Accumulate in the Central Nervous System of Patients with Multiple Sclerosis. Am J Pathol 159:1701–1710PubMed

52.

Tsai HH, Frost E, To V et al. (2002) The chemokine receptor CXCR2 controls positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration. Cell 110:373–383PubMed

53.

Van Der Voorn P, Tekstra J, Beelen RH, Tensen CP, Van Der Valk P, de Groot CJ (1999) Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions. Am J Pathol 154:45–51PubMed

54.

White JR, Lee JM, Young PR et al. (1998) Identification of a potent selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 273:10095–10098CrossRefPubMed

55.

Youssef S, Wildbaum G, Karin N (1999) Prevention of experimental autoimmune encephalomyelitis by MIP-1alpha and MCP-1 naked DNA vaccines. J Autoimmun 13:21–29CrossRefPubMed

56.

Zlotnik A, Yoshie O (2000) Chemokines: a new classification system and their role in immunity. Immunity 12:121–127PubMed

57.

Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR (1998) Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393:595–599CrossRefPubMed

Titel: Chemokine
Neue Therapieansätze für die Multiple Sklerose?
verfasst von: Dr. C. Trebst
R. M. Ransohoff
A. Windhagen
M. Stangel
Publikationsdatum: 01.10.2003
Verlag: Springer-Verlag
Erschienen in: Der Nervenarzt / Ausgabe 10/2003
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI: https://doi.org/10.1007/s00115-003-1571-9

Neu in den Fachgebieten Neurologie und Psychiatrie

25.04.2024 | Hypotonie | Nachrichten

Springer Medizin

Chemokine

Neue Therapieansätze für die Multiple Sklerose?

Zusammenfassung

Neu in den Fachgebieten Neurologie und Psychiatrie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2003

Psychosomatischer Liaisondienst in der Neurologie

Polyneuropathie als einziges paraneoplastisches Syndrom bei malignem Thymom

"Visuelles Suchen" bei Gesunden und Patienten mit Alzheimer-Erkrankung

Elektrophysiologisches Schädigungsprofil von Patienten mit einem Morbus Wilson

Lamotrigin bei Frauen mit Epilepsie

Spätmanifestation einer Glykogenose Typ II

Neu in den Fachgebieten Neurologie und Psychiatrie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet